Latest - Page 2 of 4 - Rivervest - News & Press / Case Studies / Articles

News & Press

Life sciences VC RiverVest Expands Team with New Managing Director and Senior Associate

News & Press

RiverVest Mourns Passing of Co-Founder Andrew B. Craig III

News & Press

RiverVest Builds Another San Diego Based Biopharma Company

News & Press

Sivan Weitzman Joins RiverVest Venture Partners as CFO

News & Press

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

News & Press

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

U.S. FDA Approves LIVMARLI (Maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older – 9/29/2021
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase ½ Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors – 9/16/2021
Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia – 9/9/2021
Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality – 8/17/2021
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates – 8/10/2021
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results – 8/9/2021
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update – 8/5/2021
SeQure Dx Announces $17.5M Series A Funding – 8/3/2021
Mirum Pharmaceuticals And GC Pharma Enter Into Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea – 7/26/2021
Wugen Raises $172 Million to Advance Clinical State Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials – 7/15/2021
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System – 06/29/2021
Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients – 6/29/2021
Mirum Pharmaceuticals Presents Analyses From Its Rare Disease Programs at the EASL International Liver Congress 2021 – 6/23/2021
Spruce Biosciences Announces Publication Of Phase 2 Results For Tildacerfont In Journal Of Clinical Endocrinology And Metabolism – 6/21/2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors – 6/17/2021
Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy – 6/1/2021
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology – 5/24/2021
New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms – 5/24/2021
Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology – 5/22/2021
Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results – 5/20/2021
Sparrow Pharmaceuticals Secures $50 Million Series A Financing – 5/18/2021
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates – 5/12/2021
Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at
Frontiers in Cancer Immunotherapy Virtual Symposium – 5/12/2021
OncoResponse Appoints Chris Russell as Chief Financial Officer – 5/11/2021
Allakos Reports First Quarter 2021 Financial Results and Provides Business Update – 5/10/2021
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update – 5/6/2021
Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance – 5/4/2021
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases – 4/29/2021
Pfizer Acquires Amplyx Pharmaceuticals – 4/28/2021
Arch Oncology Secures $105 Million Series C Financing – 4/27/2021
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille Syndrome – 4/26/2021
Wugen Appoints Daniel Kemp Ph.D., as Chief Executive Officer – 4/14/2021
Cardialen Announces Positive Results from Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation – 4/13/2021
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestatis – 4/12/2021
Arch Oncology Presents New Preclinical T-ALL Data on Highly Differentiated Anti-CD47 Antibody AO-176 – 4/10/2021
Reneo Pharmaceuticals Announces Pricing of Initial Public Offering – 4/8/2021
OncoResponse Raises $40.6 Million in Series C Financing – 3/31/2021
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting – 3/30/2021
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives – 3/29/2021

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Learn More

Life sciences VC RiverVest Expands Team with New Managing Director and Senior Associate

RiverVest Mourns Passing of Co-Founder Andrew B. Craig III

RiverVest Builds Another San Diego Based Biopharma Company

Sivan Weitzman Joins RiverVest Venture Partners as CFO

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

RiverVest Venture Partners’ Portfolio Company Securus Sold to Boston Scientific Represents 9th Exit from RiverVest Venture Fund II

Get Directions

Get Directions

Get Directions